Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153


Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library.

Zhou M, Meyer T, Koch S, Koch J, von Briesen H, Benito JM, Soriano V, Haberl A, Bickel M, Dübel S, Hust M, Dietrich U.

Eur J Immunol. 2013 Feb;43(2):499-509. doi: 10.1002/eji.201242974. Epub 2012 Dec 27.


Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice.

Zhou M, Kostoula I, Brill B, Panou E, Sakarellos-Daitsiotis M, Dietrich U.

Vaccine. 2012 Mar 2;30(11):1911-6. doi: 10.1016/j.vaccine.2012.01.026. Epub 2012 Jan 23.


Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.

Tudor D, Yu H, Maupetit J, Drillet AS, Bouceba T, Schwartz-Cornil I, Lopalco L, Tuffery P, Bomsel M.

Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12680-5. doi: 10.1073/pnas.1200024109. Epub 2012 Jun 20.


Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.

Trott M, Weiβ S, Antoni S, Koch J, von Briesen H, Hust M, Dietrich U.

PLoS One. 2014 May 14;9(5):e97478. doi: 10.1371/journal.pone.0097478. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e107089.


N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.

Li D, Liu J, Zhang L, Xu T, Chen J, Wang L, Zhao Q.

Virol Sin. 2015 Dec;30(6):449-56. doi: 10.1007/s12250-015-3664-6. Epub 2015 Dec 21.


Mimotopes selected by biopanning with high-titer HIV-neutralizing antibodies in plasma from Chinese slow progressors.

Zhang X, Han X, Dai D, Bao M, Zhang Z, Zhang M, Bice T, Zhao M, Cao Y, Shang H.

Braz J Infect Dis. 2012 Nov-Dec;16(6):510-6. doi: 10.1016/j.bjid.2012.07.003. Epub 2012 Nov 9.


Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Diomede L, Nyoka S, Pastori C, Scotti L, Zambon A, Sherman G, Gray CM, Sarzotti-Kelsoe M, Lopalco L.

J Virol. 2012 Apr;86(8):4129-38. doi: 10.1128/JVI.06359-11. Epub 2012 Feb 1.


Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.

Veiga AS, Pattenden LK, Fletcher JM, Castanho MA, Aguilar MI.

Chembiochem. 2009 Apr 17;10(6):1032-44. doi: 10.1002/cbic.200800609.


Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.

Guenaga J, Wyatt RT.

PLoS Pathog. 2012;8(7):e1002806. doi: 10.1371/journal.ppat.1002806. Epub 2012 Jul 19.


Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.

Maeso R, Huarte N, Julien JP, Kunert R, Pai EF, Nieva JL.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):863-76. doi: 10.1089/AID.2010.0265. Epub 2011 Jan 15.


Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes.

Franquelim HG, Chiantia S, Veiga AS, Santos NC, Schwille P, Castanho MA.

AIDS. 2011 Feb 20;25(4):419-28. doi: 10.1097/QAD.0b013e328342ff11.


Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.

Ye L, Wen Z, Dong K, Wang X, Bu Z, Zhang H, Compans RW, Yang C.

PLoS One. 2011;6(5):e14813. doi: 10.1371/journal.pone.0014813. Epub 2011 May 19.


Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.

Ma BJ, Alam SM, Go EP, Lu X, Desaire H, Tomaras GD, Bowman C, Sutherland LL, Scearce RM, Santra S, Letvin NL, Kepler TB, Liao HX, Haynes BF.

PLoS Pathog. 2011 Sep;7(9):e1002200. doi: 10.1371/journal.ppat.1002200. Epub 2011 Sep 1.


In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD.

J Virol. 2009 Apr;83(8):3617-25. doi: 10.1128/JVI.02631-08. Epub 2009 Feb 4.


Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.

Venditto VJ, Wieczorek L, Molnar S, Teque F, Landucci G, Watson DS, Forthal D, Polonis VR, Levy JA, Szoka FC Jr.

Clin Vaccine Immunol. 2014 Aug;21(8):1086-93. doi: 10.1128/CVI.00320-14. Epub 2014 May 28.


Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW.

J Virol. 2001 Nov;75(22):10892-905.


Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

Conley AJ, Kessler JA 2nd, Boots LJ, Tung JS, Arnold BA, Keller PM, Shaw AR, Emini EA.

Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3348-52.


Constrained peptide models from phage display libraries highlighting the cognate epitope-specific potential of the anti-HIV-1 mAb 2F5.

Palacios-Rodríguez Y, Gazarian T, Huerta L, Gazarian K.

Immunol Lett. 2011 Apr 30;136(1):80-9. doi: 10.1016/j.imlet.2010.12.008. Epub 2011 Jan 13.


Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.

Banerjee S, Shi H, Banasik M, Moon H, Lees W, Qin Y, Harley A, Shepherd A, Cho MW.

Virology. 2017 May;505:113-126. doi: 10.1016/j.virol.2017.02.015. Epub 2017 Feb 23.


Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals.

Molinos-Albert LM, Carrillo J, Curriu M, Rodriguez de la Concepción ML, Marfil S, García E, Clotet B, Blanco J.

Retrovirology. 2014 Jun 7;11:44. doi: 10.1186/1742-4690-11-44.

Supplemental Content

Support Center